Benitec Ends Royalty Obligations to CSIRO in Exchange for 10 Percent Stake
January 07, 2010
Benitec Ends Royalty Obligations to CSIRO in Exchange for 10 Percent Stake
Benitec said that it has also re-obtained a royalty stream paid by Sigma-Aldrich stemming from a license to its expressed RNAi technology for use in making and selling research products.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Benitec Closes Financing, Passes RAC Meeting as it Nears the Clinic
June 13, 2013 / Gene Silencing News - Benitec Plans to Advance Lung Cancer Drug into Clinic
June 6, 2013 / Gene Silencing News - Genable Receives FDA Orphan Drug Status for Ocular Disease Drug
April 18, 2013 / Gene Silencing News - UC, San Diego Selected as Site for Benitec HCV Drug Trial
April 18, 2013 / Gene Silencing News - Benitec Announces Positive Animal Data with Lung Cancer Drug Candidate
April 11, 2013 / Gene Silencing News